August 1, 2024 08:56 AM EDT
Deals
Pharma

Ab­b­Vie clos­es $8.7B Cerev­el deal in bid to com­pete with Bris­tol My­ers in schiz­o­phre­nia

Kyle LaHucik

Senior Reporter

Ab­b­Vie has re­ceived reg­u­la­to­ry clear­ance to com­plete its $8.7 bil­lion ac­qui­si­tion of neu­ro­science biotech Cerev­el Ther­a­peu­tics, the com­pa­nies

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times